Ingrid L Scully
Overview
Explore the profile of Ingrid L Scully including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
2236
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Senders S, Klein N, Tamimi N, Thompson A, Baugher G, Trammel J, et al.
Pediatr Infect Dis J
. 2024 Mar;
43(6):596-603.
PMID: 38535409
Background: The 20-valent pneumococcal conjugate vaccine (PCV20) was developed to extend pneumococcal disease protection beyond 13-valent PCV (PCV13). Methods: This phase 3, double-blind study conducted in the United States/Puerto Rico...
2.
Meyer J, Silas P, Ouedraogo G, McElwee K, Keep G, Trammel J, et al.
Pediatr Infect Dis J
. 2024 Mar;
43(6):574-581.
PMID: 38502894
Background: A 20-valent pneumococcal conjugate vaccine (PCV20), containing 13-valent PCV (PCV13) components and 7 additional polysaccharide conjugates, was developed to extend protection for pneumococcal disease. This phase 3 study assessed...
3.
Frenck Jr R, Laudat F, Liang J, Giordano-Schmidt D, Jansen K, Gruber W, et al.
Pediatr Infect Dis J
. 2023 Sep;
42(12):1045-1050.
PMID: 37768176
Background: Group A streptococci (GAS) are a major cause of pharyngitis in children. Recently, there were severe GAS outbreaks. The aims of this study were to assess pharyngeal colonization prevalence...
4.
Sackett K, Brown P, Dutta K, Scully I, Gangolli S, Looi K, et al.
J Immunol
. 2023 Feb;
210(6):764-773.
PMID: 36723033
Implementation of conjugate vaccine technology revolutionized the ability to effectively elicit long-lasting immune responses to bacterial capsular polysaccharides. Although expansion of conjugate vaccine serotype coverage is designed to target residual...
5.
Winokur P, Gayed J, Fitz-Patrick D, Thomas S, Diya O, Lockhart S, et al.
N Engl J Med
. 2023 Jan;
388(3):214-227.
PMID: 36652353
Background: The emergence of immune-escape variants of severe acute respiratory syndrome coronavirus 2 warrants the use of sequence-adapted vaccines to provide protection against coronavirus disease 2019. Methods: In an ongoing...
6.
Hao L, Kuttel M, Ravenscroft N, Thompson A, Prasad A, Gangolli S, et al.
Vaccine
. 2022 Jul;
40(33):4872-4880.
PMID: 35810060
Protection conferred by pneumococcal polysaccharide conjugate vaccines (PCVs) is associated with PCV-induced antibodies against vaccine-covered serotypes that exhibit functional opsonophagocytic activity (OPA). Structural similarity between capsular polysaccharides of closely related...
7.
Essink B, Sabharwal C, Cannon K, Frenck R, Lal H, Xu X, et al.
Clin Infect Dis
. 2021 Dec;
75(3):390-398.
PMID: 34940806
Background: Pneumococcal conjugate vaccines (PCVs) have significantly reduced pneumococcal disease, but disease from non-PCV serotypes remains. The safety, tolerability, and immunogenicity of a 20-valent PCV (PCV20) were evaluated. Methods: This...
8.
Cannon K, Elder C, Young M, Scott D, Scully I, Baugher G, et al.
Vaccine
. 2021 Nov;
39(51):7494-7502.
PMID: 34839993
Introduction: A 20-valent pneumococcal conjugate vaccine, PCV20, was developed to expand protection against vaccine-preventable pneumococcal disease. PCV20 contains the components of the 13-valent pneumococcal conjugate vaccine, PCV13, and includes capsular...
9.
Klein N, Peyrani P, Yacisin K, Caldwell N, Xu X, Scully I, et al.
Vaccine
. 2021 Jul;
39(38):5428-5435.
PMID: 34315611
Introduction: Introduction of pneumococcal conjugate vaccines (PCVs), including the 13-valent PCV (PCV13), has considerably reduced pneumococcal disease burden. However, additional serotypes not in PCV13 continue to present a substantial disease...
10.
Essink B, Peterson J, Yacisin K, Lal H, Mirza S, Xu X, et al.
Hum Vaccin Immunother
. 2021 Mar;
17(8):2691-2699.
PMID: 33661716
Pneumococcal disease can be serious and debilitating in older adults. Pneumococcal conjugate vaccines (PCVs), such as the 13-valent PCV (PCV13), reduce pneumococcal disease rates caused by vaccine serotypes. Development of...